A phase 1/2 study is currently underway to evaluate SAR446268 in participants aged 10 to 50 years with non-congenital myotonic dystrophy type 1.
TipRanks on MSN
Incyte price target raised to $81 from $72 at RBC Capital
RBC Capital raised the firm’s price target on Incyte (INCY) to $81 from $72 and keeps a Sector Perform rating on the shares. The company’s ‘989 ...
Discover Quince Therapeutics’ breakthrough drug-delivery platform aiming to safely treat rare diseases with encapsulated steroids.
In view of persistent fever and cough, and the new onset of an accentuated confluent maculopapular rash, the patient was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback